文献速递胸部肿瘤

被动散射质子治疗与调强光子放疗在局部晚期非小细胞肺癌中的贝叶斯自适应随机试验

Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer.
PubMed 文献 · J Clin Oncol · 2018-01-02

这项随机试验比较了被动散射质子治疗(PSPT)与调强光子放疗(IMRT)联合同步化疗治疗不可手术非小细胞肺癌(NSCLC)的结局。主要终点为≥3级放射性肺炎(RP)和局部失败(LF)。结果显示PSPT未改善肺的剂量体积指标但改善了心脏指标,RP或LF均无获益,试验过程中两个终点均有改善。

要点

  • PSPT与IMRT相比,肺受5-10 Gy(RBE)剂量体积更小,但≥20 Gy(RBE)体积更大。
  • PSPT在所有5-80 Gy(RBE)剂量水平上心脏受照体积更小。
  • PSPT未改善RP或LF,试验过程中两个终点均有改善。

核心结论

  • PSPT未改善肺的剂量体积指标但改善了心脏指标,RP或LF均无获益。

研究设计与样本

  • 随机试验比较PSPT与IMRT联合同步化疗治疗不可手术NSCLC,主要终点为≥3级RP和LF。
  • 入组患者为IIB至IIIB期NSCLC(或IV期伴单个脑转移或术后复发肺/纵隔病变)适合同步放化疗者。
  • 每例患者均创建IMRT和PSPT治疗计划,仅当两种计划均满足相同预设剂量体积约束时才随机分配。

主要发现

  • PSPT(n=57)与IMRT(n=92)相比,肺受5-10 Gy(RBE)剂量体积更小,但≥20 Gy(RBE)体积更大。
  • PSPT在所有5-80 Gy(RBE)剂量水平上心脏受照体积更小。
  • 所有患者≥3级RP率为8.1%(IMRT 6.5%;PSPT 10.5%),LF率分别为10.7%(全部)、10.9%(IMRT)、10.5%(PSPT)。
  • IMRT优于PSPT的后验概率为0.54。
  • 探索性分析显示12个月RP和LF率在试验中点前后入组患者中:IMRT组21.1%(前)vs 18.2%(后)(P=.047),PSPT组31.0%(前)vs 13.1%(后)(P=.027)。

临床怎么用

  • PSPT未显示在RP或LF方面优于IMRT,但心脏受照剂量更低。
  • 试验过程中RP和LF均有改善,提示随着时间推移治疗技术或管理可能进步。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose This randomized trial compared outcomes of passive scattering proton therapy (PSPT) versus intensity-modulated (photon) radiotherapy (IMRT), both with concurrent chemotherapy, for inoperable non-small-cell lung cancer (NSCLC). We hypothesized that PSPT exposes less lung tissue to radiation than IMRT and thereby reduces toxicity without compromising tumor control. The primary end points were grade ≥ 3 radiation pneumonitis (RP) and local failure (LF). Patients and Methods Eligible patients had stage IIB to IIIB NSCLC (or stage IV NSCLC with a single brain metastasis or recurrent lung or mediastinal disease after surgery) who were candidates for concurrent chemoradiation therapy. Pairs of treatment plans for IMRT and PSPT were created for each patient. Patients were eligible for random assignment only if both plans satisfied the same prespecified dose-volume constraints for at-risk organs at the same tumor dose. Results Compared with IMRT (n = 92), PSPT (n = 57) exposed less lung tissue to doses of 5 to 10 Gy(RBE), which is the absorbed Gy dose multiplied by the relative biologic effectiveness (RBE) factor for protons; exposed more lung tissue to ≥ 20 Gy(RBE), but exposed less heart tissue at all dose levels between 5 and 80 Gy(RBE). The grade ≥ 3 RP rate for all patients was 8.1% (IMRT, 6.5%; PSPT, 10.5%); corresponding LF rates were 10.7% (all), 10.9% (IMRT), and 10.5% (PSPT). The posterior probability of IMRT being better than PSPT was 0.54. Exploratory analysis showed that the RP and LF rates at 12 months for patients enrolled before versus after the trial midpoint were 21.1% (before) versus 18.2% (after) for the IMRT group (P = .047) and 31.0% (before) versus 13.1% (after) for the PSPT group (P = .027). Conclusion PSPT did not improve dose-volume indices for lung but did for heart. No benefit was noted in RP or LF after PSPT. Improvements in both end points were observed over the course of the trial.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Liao Z, Lee JJ, Komaki R, et al. Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2018. PMID: 29293386. doi:10.1200/JCO.2017.74.0720

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。